Sorafenib in advanced melanoma: a critical role for pharmacokinetics? - Wikidata - wikimedia - TriplyDB

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

http://www.wikidata.org/entity/Q36117220

about

Emerging targeted therapies for melanoma treatment (review)Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring.Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.Emerging growth factor receptor antagonists for the treatment of advanced melanoma.Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth Commentary on: "Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide".Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS).CLC-Pred: A freely available web-service for in silico prediction of human cell line cytotoxicity for drug-like compounds.Pharmacokinetic-Guided Dosing of New Oral Cancer Agents.Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance.How 'Optimal' are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations.Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study.

P2860

Q26829997-27E9E72B-9D75-4697-88BB-F94666629577 Q33411001-5F65D920-1448-44F8-A49B-D7668C34E33F Q36060211-4C71197D-151F-436F-9C07-A4CA56DF3019 Q37665918-98FE6909-A781-4253-A2A0-375084F9B391 Q38091649-AFD22DD8-106A-42F0-B544-D8B207526BD3 Q38201503-E8BB5C1F-D328-465A-97D6-60A345D910FB Q39340696-00FFD489-4941-4000-98B3-F35896238F80 Q39413595-8571FBBB-878D-4FD2-B273-0DFAA3770A2C Q40976710-D3D70282-BA91-48C0-9BFC-89BE27AF52D8 Q44252023-DDF1A80B-F76D-4613-8946-D750B466C73E Q47556436-4EE31350-C95F-47A6-B1BC-15CD445A6267 Q47969048-C34293D2-6E2C-4EDE-A16E-EE1C6C6EF412 Q48217300-71FF923A-87A7-4AEC-8DDB-B3BBCAF9EC19 Q48826707-27AEC114-123A-4F48-896B-E8008E9FA3EB Q52941893-EA0A2608-415F-4A37-93FA-2F406FA205BC

P2860

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

http://www.wikidata.org/entity/Q36117220

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

@ast

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

@en

type

label

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

@ast

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

@en

prefLabel

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

@ast

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

@en

P1433

Q36117220-00D240B4-09BE-41FE-B0D2-0DA74A9E08CC

P1476

Q36117220-DF38D5EF-C5F2-4121-B2EA-1A382B23DC1A

P2093

Q36117220-05A74DD9-749B-4B50-B631-F7816B71C398

Q36117220-3B1AA50A-5D3B-46C7-ADC9-E18E82F1F950

Q36117220-454B0798-97A9-4B86-9578-B350A56F530B

Q36117220-6E0DB39B-F188-4411-9753-BF03137270C6

Q36117220-723E1B82-6117-4109-BE7A-C3FD61262CA9

Q36117220-7284D7FE-552A-4758-85A8-9567E0F7801B

Q36117220-72BE0367-CBEA-4D92-B05B-76C3BED5656B

Q36117220-80899CB6-77C6-46D8-BE75-E3DAD31C50BC

Q36117220-E5BFED02-C235-45E7-92AD-C7C9F240FBF5

P2860

Q36117220-01589C37-4BAB-48DE-9AFB-39D38A3419C6

Q36117220-01E162DF-533E-49D1-A7EE-A736BB295D08

Q36117220-0DB2CF24-F850-43D6-AE64-F683523053D9

Q36117220-1A3F79F2-279F-4222-9F85-98104FCE9633

Q36117220-1C509E5D-D3E7-4871-99B5-1B11AD5B845E

Q36117220-207B33B3-E186-48FB-A7FB-08E213E999E0

Q36117220-21EF5D1C-EC7F-4A79-AE6C-6E9D991C1A4C

Q36117220-2C43690C-9E27-42BE-9642-59FB2F1E2295

Q36117220-3437833B-FE9A-4EEB-91B3-FC618A06FF16

Q36117220-3C82BD77-C09B-4A96-A796-02586A57D456

P2888

Q36117220-85B2035F-CC33-4A51-957A-CFC6B28672B8

P304

Q36117220-AACEDDBE-69A7-4D89-A294-EDA0343A5B25

P31

Q36117220-472EF420-69AC-4A23-B28E-5A44942FD333

P356

Q36117220-E82153BE-905A-4621-91BD-DD117D865ACB

P407

Q36117220-701A0DE6-857B-4F09-8B9B-B9451608857F

P433

Q36117220-5157AD86-A3DD-45B5-8BBA-E36F85AE300F

P478

Q36117220-947B8296-116D-4336-BA0F-366154F31C92

P50

Q36117220-0464F3ED-9A95-4AB3-8A72-C023778A3D6D

Q36117220-B09FBC02-6B24-4594-8FE9-25EF40DDC928

P577

Q36117220-1235736B-787E-4D94-A8C5-59659B623AD7

P5875

Q36117220-65CD840B-04A5-47AD-84C5-43136AEB5A55

P698

Q36117220-9921187A-F438-4B44-8E44-1CE2CF0630A2

P932

Q36117220-9CD58164-3474-4B86-9A4F-11262C67934D

P356

P1433

British Journal of Cancer

P1476

Sorafenib in advanced melanoma: a critical role for pharmacokinetics?

@en

P2093

B Billemont

http://www.w3.org/2001/XMLSchema#string

B Blanchet

http://www.w3.org/2001/XMLSchema#string

C Lebbe

http://www.w3.org/2001/XMLSchema#string

F Goldwasser

http://www.w3.org/2001/XMLSchema#string

M Tod

http://www.w3.org/2001/XMLSchema#string

M Viguier

http://www.w3.org/2001/XMLSchema#string

M-F Avril

http://www.w3.org/2001/XMLSchema#string

N Franck

http://www.w3.org/2001/XMLSchema#string

R Coriat

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in GNA11 in uveal melanoma

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

A phase II trial of sorafenib in metastatic melanoma with tissue correlates.

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

P2888

P304

455-461

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2012.287

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Nicolas Pécuchet

P577

2012-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

228330935

http://www.w3.org/2001/XMLSchema#string

P698

22767146

http://www.w3.org/2001/XMLSchema#string

P932

3405224

http://www.w3.org/2001/XMLSchema#string